Literature DB >> 28175307

Changes in bone turnover markers with HIV seroconversion and ART initiation.

Laurence Slama1,2, Susheel Reddy2, John Phair2, Frank J Palella2, Todd T Brown3.   

Abstract

Background: Osteoporosis is common among HIV-infected persons and contributes to risk of fragility fracture. While ART initiation is associated with decreases in bone mineral density and increases in bone turnover, the impact of HIV on bone metabolism is unclear.
Methods: We identified men at the Chicago site of the Multicenter AIDS Cohort Study who HIV seroconverted while under observation. Concentrations of 25-OH vitamin D, bone turnover markers [procollagen type 1 N terminal propeptide (P1NP), osteocalcin (OC), C-telopeptide (CTX)] and sclerostin were measured from stored serum obtained at pre-HIV infection, pre-ART and post-ART initiation timepoints. Mixed models, with each biomarker as an outcome, were fitted. Timepoint, age, CD4 count (cells/mm 3 ), HIV-viral suppression, season and an age by timepoint interaction term were considered as fixed effects.
Results: Data from 52 participants revealed that median duration between HIV seroconversion and ART initiation was 8.7 years (IQR 3.7-11.6). Median CD4 and plasma HIV-RNA concentrations were 445 (IQR 298.5-689) and 20 184 copies/mL (IQR 6237-64 340), respectively, at the pre-ART timepoint. Multivariate analyses demonstrated pre-HIV infection levels of OC that were higher than pre-ART levels (6.8 versus 5.7 ng/mL, P  =   0.04); and pre-ART levels of sclerostin that were higher than post-ART levels (0.033 versus 0.02 ng/mL, P  <0.001). No changes in P1NP, CTX and 25-OH vitamin D levels were detected. Conclusions: HIV seroconversion was associated with decreased OC levels while ART initiation was associated with decreases in sclerostin, a negative regulator of bone formation. Our results suggest that both HIV infection and ART have an impact on bone metabolism in white men.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28175307      PMCID: PMC5890782          DOI: 10.1093/jac/dkx011

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  31 in total

Review 1.  Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton.

Authors:  Roland Baron; Georges Rawadi
Journal:  Endocrinology       Date:  2007-03-29       Impact factor: 4.736

Review 2.  A review of osteocyte function and the emerging importance of sclerostin.

Authors:  Jocelyn T Compton; Francis Y Lee
Journal:  J Bone Joint Surg Am       Date:  2014-10-01       Impact factor: 5.284

3.  Lower fracture risk in older men with higher sclerostin concentration: a prospective analysis from the MINOS study.

Authors:  Pawel Szulc; Cindy Bertholon; Olivier Borel; Francois Marchand; Roland Chapurlat
Journal:  J Bone Miner Res       Date:  2013-04       Impact factor: 6.741

4.  Changes in bone mineral density after 96 weeks of treatment with atazanavir/ritonavir or lopinavir/ritonavir plus tenofovir DF/emtricitabine in treatment-naive patients with HIV-1 infection: the CASTLE body composition substudy.

Authors:  Graeme J Moyle; Hélène Hardy; Awny Farajallah; St John McGrath; Stephen Kaplita; Douglas Ward
Journal:  J Acquir Immune Defic Syndr       Date:  2015-01-01       Impact factor: 3.731

5.  Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens.

Authors:  Todd T Brown; Allison C Ross; Norma Storer; Danielle Labbato; Grace A McComsey
Journal:  Antivir Ther       Date:  2011

6.  Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels.

Authors:  Eugènia Negredo; Adolfo Diez-Pérez; Anna Bonjoch; Pere Domingo; Núria Pérez-Álvarez; Mar Gutierrez; Gracia Mateo; Jordi Puig; Patricia Echeverría; Roser Escrig; Bonaventura Clotet
Journal:  J Antimicrob Chemother       Date:  2015-03-13       Impact factor: 5.790

7.  Plasma Sclerostin in HIV-Infected Adults on Effective Antiretroviral Therapy.

Authors:  Kristine M Erlandson; MaryAnn O'Riordan; Corrilynn O Hileman; Eric Rapaport; Danielle Labbato; Thomas B Campbell; Grace A McComsey
Journal:  AIDS Res Hum Retroviruses       Date:  2015-05-27       Impact factor: 2.205

8.  Age-related reference intervals for bone turnover markers from an Australian reference population.

Authors:  N Jenkins; M Black; E Paul; J A Pasco; M A Kotowicz; H-G Schneider
Journal:  Bone       Date:  2013-04-16       Impact factor: 4.398

9.  Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection.

Authors:  Ighovwerha Ofotokun; Kehmia Titanji; Aswani Vunnava; Susanne Roser-Page; Tatyana Vikulina; Francois Villinger; Kenneth Rogers; Anandi N Sheth; Cecile Delille Lahiri; Jeffrey L Lennox; M Neale Weitzmann
Journal:  AIDS       Date:  2016-01-28       Impact factor: 4.177

10.  Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004.

Authors:  Adit A Ginde; Mark C Liu; Carlos A Camargo
Journal:  Arch Intern Med       Date:  2009-03-23
View more
  6 in total

1.  Bone and fat hormonal crosstalk with antiretroviral initiation.

Authors:  Arnold Z Olali; Qiuhu Shi; Donald R Hoover; Mariana Bucovsky; Elizabeth Shane; Michael T Yin; Ryan D Ross
Journal:  Bone       Date:  2021-09-20       Impact factor: 4.626

2.  Brief Report: Undercarboxylated Osteocalcin Is Associated With Cognition in Women With and Without HIV.

Authors:  Ryan D Ross; Arnold Z Olali; Qiuhu Shi; Donald R Hoover; Anjali Sharma; Kathleen M Weber; Audrey L French; Heather McKay; Phyllis C Tien; Michael T Yin; Leah H Rubin
Journal:  J Acquir Immune Defic Syndr       Date:  2022-10-01       Impact factor: 3.771

Review 3.  Bone Quality in Relation to HIV and Antiretroviral Drugs.

Authors:  Arnold Z Olali; Kelsey A Carpenter; Maria Myers; Anjali Sharma; Michael T Yin; Lena Al-Harthi; Ryan D Ross
Journal:  Curr HIV/AIDS Rep       Date:  2022-06-20       Impact factor: 5.495

4.  Increase in bone turnover markers in HIV patients treated with tenofovir disoproxil fumarate combined with raltegravir or efavirenz.

Authors:  Yonatan Oster; Matan J Cohen; Rivka Dresner-Pollak; Auryan Szalat; Hila Elinav
Journal:  Bone Rep       Date:  2020-10-16

5.  Impact of HIV-1 Infection and Antiretroviral Therapy on Bone Homeostasis and Mineral Density in Vertically Infected Patients.

Authors:  D Donà; E Mozzo; D Luise; R Lundin; A Padoan; O Rampon; C Giaquinto
Journal:  J Osteoporos       Date:  2019-01-01

6.  Change in Circulating Undercarboxylated Osteocalcin (ucOCN) Is Associated With Fat Accumulation in HIV-Seropositive Women.

Authors:  Arnold Z Olali; Anjali Sharma; Qiuhu Shi; Donald R Hoover; Kathleen M Weber; Audrey L French; Heather S McKay; Phyllis C Tien; Lena Al-Harthi; Michael T Yin; Ryan D Ross
Journal:  J Acquir Immune Defic Syndr       Date:  2021-04-15       Impact factor: 3.771

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.